Stay updated on Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.1%

- Check41 days agoChange DetectedRevision badge updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check62 days agoChange DetectedMinor site revision update to v3.4.2 from v3.4.1; no changes to study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check70 days agoChange DetectedThe page now displays Revision: v3.4.1 and no longer displays Revision: v3.4.0.SummaryDifference0.1%

- Check84 days agoChange DetectedA glossary toggle was added; QC-related metadata labels were updated to display 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0', replacing the previous labels.SummaryDifference0.3%

- Check91 days agoChange DetectedThe page revision was updated from v3.3.3 to v3.3.4. No study content or critical information appears to have changed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.